Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Becker, A; Placke, A; Kluth, L; Schwarz, R; Isbarn, H; Chun, F; Heuer, R; Schlomm, T; Seiler, D; Engel, O; Fisch, M; Graefen, M; Ahyai, SA.
Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study.
J Endourol. 2014; 28(3):335-41 Doi: 10.1089/end.2013.0432
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Ahyai Sascha
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly. RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP. CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.
Find related publications in this database (using NLM MeSH Indexing): Aged - administration & dosage; Aged, 80 and over - administration & dosage; Feasibility Studies - administration & dosage; Follow-Up Studies - administration & dosage; Humans - administration & dosage; Laser Therapy - methods; Lasers, Solid-State - therapeutic use; Lower Urinary Tract Symptoms - complications, physiopathology; Male - administration & dosage; Middle Aged - administration & dosage; Prostatectomy - methods; Prostatic Neoplasms - complications, surgery; Quality of Life - administration & dosage; Retrospective Studies - administration & dosage; Treatment Outcome - administration & dosage; Urination - administration & dosage